Analysis of nocebo effects of antiepileptic drugs across different conditions

Journal of Neurology
Gaetano ZaccaraSara Gasparini

Abstract

The aim of this study was to assess the nocebo effect in all randomised controlled trials (RCTs) exploring the effect of antiepileptic drugs (AEDs) in the clinical conditions in which these compounds have been studied with the exception of epilepsy. We searched for all double-blind, placebo-controlled trials performed in adult patients, testing AEDs in any clinical condition except epilepsy. The following data were extracted from the placebo arms: the number of randomized patients, the number of patients withdrawing because of adverse effects (AEs), and the number of patients with 11 predefined AEs (dizziness, ataxia/coordination abnormal, diplopia, somnolence, fatigue, headache, memory impairment, tremor, abnormal thinking, anxiety and depression). Outcome measures were the percentages of patients whithdrawing due to AEs and reporting the selected AEs. RCTs included in the analysis were grouped in six main categories of clinical conditions (pain, movement disorders, psychiatric disorders, substance abuse, obesity and binge eating disorders, and miscellanea). Proportions of patients with 95 % confidence intervals (CIs) have been calculated for all reported outcome measures. Thirteen AEDs were studied and the total number of sel...Continue Reading

References

Nov 5, 2005·CNS Drugs·Emilio Perucca, Patrick Kwan
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Dec 8, 2009·BMC Medical Research Methodology·Byron C WallaceThomas A Trikalinos
Feb 23, 2010·Lancet·Damien G FinnissFabrizio Benedetti
May 18, 2011·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Paul EnckStephan Zipfel
Jul 27, 2012·Lancet Neurology·Piero Perucca, Frank G Gilliam
Nov 14, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·P StathisD D Mitsikostas
Jul 25, 2013·Pharmacology & Therapeutics·Danielle Murray, A Jon Stoessl
Nov 12, 2013·Psychiatry Research·Dimos D MitsikostasNikolaos Chalarakis
Nov 5, 2014·The Journal of Headache and Pain·Xiang-qing WangSheng-yuan Yu
Feb 24, 2015·Epilepsy & Behavior : E&B·Gaetano ZaccaraDieter Schmidt
Sep 6, 2015·BMJ : British Medical Journal·Philip Sedgwick, Nan Greenwood

❮ Previous
Next ❯

Citations

Jul 20, 2016·Expert Opinion on Drug Metabolism & Toxicology·Sven C van DijkmanOscar Della Pasqua
Apr 6, 2017·European Journal of Clinical Pharmacology·Gaetano ZaccaraUmberto Benedetto
Sep 25, 2018·Journal of Managed Care & Specialty Pharmacy·Johlee S OdinetGregory A Heindel
Sep 9, 2018·Acta Neurologica Scandinavica·Simona LattanziFrancesco Brigo
Mar 22, 2019·Neuromodulation : Journal of the International Neuromodulation Society·Panagiotis ZisPtolemaios G Sarrigiannis
Feb 7, 2019·BMC Medicine·Panagiotis Zis, Panagiota Sykioti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.